SciBX: Science-Business eXchange Contents: September 18 2014, Volume 7 / Issue 36

If you are unable to see the message below, click here to view.

Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Vela Diagnostics.   TABLE OF CONTENTS September 18 2014, Volume 7 / Issue 36 Analysis Cover Story Translational Notes Tools The Distillery: Therapeutics Cancer Dermatology Endocrine/metabolic disease Hematology Infectious disease Inflammation Musculoskeletal disease Neurology The Distillery: Techniques Assays and screens Disease models Drug platforms Imaging Markers Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with ATCC.   Analysis Cover Story Top Neutralizing HIV rebound Benjamin Boettner doi:10.1038/scibx.2014.1059 Rockefeller University researchers have shown that broadly neutralizing antibodies against HIV envelope proteins can knock the virus out of its latent reservoirs, thus opening an inroad to fully eliminating HIV from infected individuals. Full Text | PDF Translational Notes Top The FDA's push for better biomarkers Lauren Martz doi:10.1038/scibx.2014.1060 The FDA is calling on stakeholders to help define a path for validating and approving biomarkers to enable their use in drug development. Full Text | PDF Translational tidbits Gaspar Taroncher-Oldenburg, Chris Cain and Kai-Jye Lou doi:10.1038/scibx.2014.1061 The FDA reviews the status of RNA sequencing; Serono builds on its lupus partnerships; Genomics England receives over £300 million ($500 million) in new investments; a roundup of recent public-private partnerships. Full Text | PDF Tools Top Bad blood Tracey Baas doi:10.1038/scibx.2014.1062 Whereas pharmacological approaches to treat sepsis have languished in the clinic, a microfluidic device developed by a Massachusetts team cleanses pathogens and endotoxins from blood and increases survival in rat models of sepsis. Full Text | PDF Distillery: Therapeutics Cancer Top Lysine-specific demethylase 6A (KDM6A; UTX); KDM6B (JMJD3) doi:10.1038/scibx.2014.1063 Cell culture and mouse studies suggest inhibiting JMJD3 could help treat T cell acute lymphoblastic leukemia (T-ALL). Full Text | PDF Neurofibromin 1 (NF1); MEK; suppressor of zeste 12 homolog (SUZ12); bromodomain containing 4 (BRD4) doi:10.1038/scibx.2014.1064 Human sample and mouse studies suggest combined inhibition of MEK and BRD4 could help treat patients with Ras-driven brain tumors. Full Text | PDF Junction plakoglobin (JUP) doi:10.1038/scibx.2014.1065 Studies in mice and patient samples suggest JUP inhibition could help prevent breast cancer metastasis. Full Text | PDF BRAF; eukaryotic translation initiation factor 4A1 (eIF4A1); eIF4F; MEK doi:10.1038/scibx.2014.1066 Studies in patient samples, mice and cell culture suggest disrupting the eIF4F complex could be useful for treating cancers resistant to BRAF and MEK inhibitors. Full Text | PDF K-Ras (KRAS) doi:10.1038/scibx.2014.1067 Mouse studies suggest inhibiting oxidative phosphorylation could help overcome resistance to oncogene-ablating therapies in patients with pancreatic ductal adenocarcinoma. Full Text | PDF L1 cell adhesion molecule (L1CAM; CD171) doi:10.1038/scibx.2014.1068 Studies in patient samples and mice suggest inhibiting CD171 could help treat pancreatic cancer. Full Text | PDF EPH receptor A3 (EPHA3) doi:10.1038/scibx.2014.1069 In vitro and mouse studies suggest EPHA3 antibodies could help treat solid tumors. Full Text | PDF Dermatology Top Janus kinase (JAK) doi:10.1038/scibx.2014.1070 Mouse studies suggest JAK inhibitors could help treat alopecia areata (AA). Full Text | PDF Endocrine/metabolic disease Top α-L-iduronidase (IDUA) doi:10.1038/scibx.2014.1071 Feline studies suggest intrathecal IDUA gene therapy could help treat mucopolysaccharidosis I (MPS I), which is caused by a deficiency in the gene and characterized by glycosaminoglycan accumulation in various tissues. Full Text | PDF Hematology Top Acyl-CoA synthetase short-chain family member 2 (ACSS2); endothelial PAS domain protein 1 (EPAS1; HIF2A); erythropoietin (EPO) doi:10.1038/scibx.2014.1072 Mouse studies suggest acetate supplementation could help treat acute anemia. Full Text | PDF Infectious disease Top Not applicable doi:10.1038/scibx.2014.1073 Studies of patient serum samples have identified antibodies targeting multiple Plasmodium falciparum merozoite surface antigens that could protect against blood-stage malaria. Full Text | PDF Inflammation Top Not applicable doi:10.1038/scibx.2014.1074 Mouse studies suggest fibroblastic reticular cell (FRC) therapy could help treat sepsis. Full Text | PDF Musculoskeletal disease Top Dystrophin (DMD) doi:10.1038/scibx.2014.1075 Mouse studies suggest clustered, regularly interspaced short palindromic repeats (CRISPR)-mediated genome editing could be used to help treat DMD. Full Text | PDF Neurology Top Type I interferon receptor (IFN receptor) doi:10.1038/scibx.2014.1076 Mouse studies suggest neutralizing IFN receptor in the CNS could help treat cognitive decline associated with aging. Full Text | PDF Aquaporin-4 (AQP4); corticotropin-releasing factor 1 (CRF1); corticotropin-releasing factor receptor 1 (CRHR1; CRFR1) doi:10.1038/scibx.2014.1077 Rat studies suggest inhibiting CRFR1 signaling could help prevent hypoxia-induced cerebral edema, which can be caused by altitude sickness. Full Text | PDF Distillery: Techniques Assays and screens Top Programmable ligand display system to identify multivalent binders to GPCRs doi:10.1038/scibx.2014.1078 A programmable ligand-display system could be useful for identifying high-affinity compounds that bind GPCR targets. Full Text | PDF Disease models Top Marmoset model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection doi:10.1038/scibx.2014.1079 The common marmoset could be useful as a model organism for studying MERS-CoV infection. Full Text | PDF Ras homolog family member T1 (Rhot1; Miro1)-deficient mouse models of motor neuron disease doi:10.1038/scibx.2014.1080 Miro1-deficient mice could be useful as models of motor neuron diseases. Full Text | PDF Drug platforms Top Biospleen platform to remove microorganisms and endotoxins from blood to treat sepsis doi:10.1038/scibx.2014.1081 In vitro and rat studies suggest a biospleen platform could be used to remove microorganisms and endotoxins from the blood to treat sepsis. Full Text | PDF Fully organized and functional thymus from reprogrammed fibroblasts doi:10.1038/scibx.2014.1082 Cell culture and mouse studies suggest fibroblasts could be reprogrammed and transplanted to produce a fully organized and functional thymus. Full Text | PDF Refillable, hydrogel-based drug delivery depots doi:10.1038/scibx.2014.1083 Hydrogel-based drug delivery depots that are refilled via direct infusion of drugs into the bloodstream could be useful systems for long-term drug delivery. Full Text | PDF Imaging Top Magnetic resonance relaxometry (MRR) for malaria diagnosis doi:10.1038/scibx.2014.1084 In vitro and mouse studies suggest MRR could help diagnose malaria from blood samples with better sensitivity and specificity than standard methods. Full Text | PDF Markers Top Glioblastoma multiforme (GBM) circulating tumor cells (CTCs) to diagnose peripheral metastases doi:10.1038/scibx.2014.1085 Studies in patient samples suggest detecting CTCs could help diagnose extracranial GBM metastasis. Full Text | PDF IL-32 as a marker of host defense against Mycobacterium tuberculosis doi:10.1038/scibx.2014.1086 IL-32 could be useful as a marker for detecting a protective host immune response against M. tuberculosis. Full Text | PDF Noninvasive diagnosis of Creutzfeldt-Jakob disease using nasal brushings or urine samples doi:10.1038/scibx.2014.1087 Two separate studies in human samples suggest Creutzfeldt-Jakob disease could be diagnosed using nasal brushings or urine samples. Full Text | PDF Top

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.